Astodrimer sodium nasal spray versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blinded, placebo-controlled trial

Winchester, S., Castellarnau, A., Jabbar, K. et al. (6 more authors) (2024) Astodrimer sodium nasal spray versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blinded, placebo-controlled trial. Pharmaceutics, 16 (9). 1173. ISSN 1999-4923

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Keywords: COVID-19; SARS-CoV-2; SPL7013; antiviral; astodrimer; dendrimer; intranasal spray
Dates:
  • Published: 6 September 2024
  • Published (online): 6 September 2024
  • Accepted: 4 September 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 11 Oct 2024 16:14
Last Modified: 11 Oct 2024 16:14
Status: Published
Publisher: MDPI AG
Refereed: Yes
Identification Number: 10.3390/pharmaceutics16091173
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics